US28176E1082
US28176E1082
Edwards Lifesciences Corporatio
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 49.06B EUR | 52.14B EUR | 46.21B EUR | 49.5B EUR |
Enterprise Value | 45.11B EUR | 52.14B EUR | 44.46B EUR | 47.27B EUR |
Valuation Multiples | ||||
Trailing P/E | 50.72x | 68.34x | 42.15x | 46.12x |
Forward P/E | 25.23x | -- | -- | -- |
Price to Sales | 7.53x | 10.93x | 7.33x | 8.16x |
Price to Book | 4.63x | -- | 4.47x | 4.79x |
EV/Revenue | 6.93x | 10.93x | 7.05x | 7.79x |
EV/EBITDA | 22.59x | 30.97x | 20.03x | 24.06x |
Price to FCF (P/FCF) | 39.81x | 61.44x | 42.41x | 37.08x |
EV/FCF | 36.61x | 61.44x | 40.81x | 35.41x |
FCF Yield | 2.51% | 1.63% | 2.36% | 2.7% |